Hematological Malignancies and Arterial Thromboembolism

Nathan Visweshwar¹ • Michael Jaglal² • Lubomir Sokol² • Benjamin Djulbegovic³

Abstract Established guidelines exist for prevention and treatment of venous thromboembolism in hematological malignancies, but none for arterial thromboembolism. However, arterial and venous thromboembolism share the same provoking features—including altered procoagulant factors and defective fibrinolytic system. The morbidity for arterial thromboembolism is increasing in hematological malignancies, with the advent of immunomodulatory and targeted therapy. However, survival rate for hematological malignancy is improving. Consequently, as patients with hematological malignancies live longer, comorbidities including diabetes, hypertension and dyslipidemia, may accentuate arterial thrombosis. Thus far, the scientific literature on prophylaxis and treatment for arterial thromboembolism in hematological malignancies is limited. This review highlights the pathogenesis, incidence and clinical features of arterial thromboembolism in hematological malignancies.

Keywords Thrombosis • Arterial • Hematological malignancies

Introduction

In peer-reviewed literature, there is wealth of information available for venous thromboembolism (VTE) for hematological malignancies, but only limited data available for arterial thromboembolism (ATE). Mortality has decreased in hospitalized patients for VTE after enforcing thromboprophylaxis, but this has not affected the ATE events. Approximately 25% of the literature in thrombosis, appears to be in ATE [1]. The incidence of ATE is increasing with the advent of biological agents, targeted therapy with tyrosine kinase inhibitors and immunomodulatory agents in hematological malignancies [2, 3]. In hospitalized neutropenic patients from 1995 to 2002, there was 124% increase in arterial events when compared to 36% increase in venous events (p < 0.0001). The in-hospital mortality was greater in arterial [odds ratio (OR) 5.04] than venous thromboembolism [OR 2.01] [4]. In a retrospective analysis of patients receiving cisplatin-based chemotherapy for lymphoma, ATE was found in 8.3% of patients, and combined VTE and ATE was seen in 3.0% of patients [5]. Overall, there is a higher incidence of ATE in patients with previous history of deep vein thrombosis—with a relative risk for myocardial infarction of 1.6 and for stroke 2.1. In patients with pulmonary embolism, relative risk for myocardial infarction is increased by 2.6 and for stroke 2.9 [6, 7]. Most of the patients with hematological malignancies and ATE have no history of diffuse vascular disease accounting for thrombosis [8]. Patients with unprovoked VTE are at risk for ATE in hematological malignancies [9]. Accelerated coronary atherosclerosis, heart transplant
atherosclerosis, vein graft disease, coronary restenosis after angioplasty may be the presenting manifestation of ATE in patients with hematological malignancy [10]. Apart from occlusion of major vessels, microvascular thrombosis may manifest as confusion, metabolic encephalopathy, widespread myocardial microthrombosis, thrombotic thrombocytopenic purpura or microemboli in skeletal muscles presenting as myositis in hematological malignancies [11]. The mechanism for ATE in hematological malignancies has not yet been characterized.

Pathogenesis

The pathophysiology of ATE in hematological malignancies is not yet scientifically proven [12]. Several factors have been implicated in the prothrombotic state associated with ATE, including abnormal coagulation pathway, microparticles, cytokines, soluble P-selectin, elevation in coagulation factors, thrombocytosis and leukocytosis [13]. There appears to be better understanding of ATE in patients with myeloproliferative disorders, chronic myeloid leukemia (CML) and in myeloma. Nonetheless, most of the factors precipitating VTE, especially unprovoked VTE appears to trigger ATE—Fig. 1 [9, 14, 15].

Abnormal Coagulation Pathway

The pathophysiology of ATE in hematological malignancy appears to be very similar to VTE, keeping in line with the three tenets of Virchow’s Triad, namely alterations in flow, abnormal cell and molecular properties and altered blood vessel walls (Table 1). The endothelial damage (Fig. 2) is exacerbated by tissue factor (TF) shed from microparticles of tumor tissue and activates platelets. This, in turn, activates the extrinsic pathway, binding factors VII and X, triggering thrombin generation [16, 17]. The activated platelets also release short-chain polyphosphates (SCP). The SCP derived from activated platelets acts as a cofactor for the inhibition of tissue pathway inhibitor alpha (TFPIα), suggesting that activated platelets in a hemostatic plug may contribute to the hemostatic role of FXI not only by enhancing the activation of FXI by thrombin and the activation of FV and FX by FXIα, but also by promoting thrombin generation through neutralization of TFPI [18]. In polycythemia Vera, increased adhesion of RBCs due to abnormal activation of adhesion proteins in RBCs to endothelium appears to contribute to thrombosis [19]. Photomicrography shows the red blood cells, leukocytes and platelets participate in development of ATE. Their mutual interaction appears to be important for thrombus formation [20]. The mechanisms of ATE in myeloma patients are multifactorial and include increased levels of procoagulant factors such as von Willebrand factor and factor VIII and high levels of inflammatory cytokines such as interleukin 6 and tumor necrosis factors [21, 22].

The Role of Platelets and Polymorphonuclear Cells

Polymorphonuclear leukocytes play a major role in pathophysiology of ATE in myeloproliferative disorders. Polymorphonuclear leukocytes promote thrombosis through interactions of several adhesion molecules with other blood cell components. Their activation is associated with thrombotic events accentuated by Janus kinase (JAK2) mutational status [23]. Once activated, neutrophils release reactive molecules that can induce endothelial functional changes [24]. Polymorphonuclear neutrophils

Fig. 1 Interaction of patient characteristics, disease characteristics and intervention in ATE of hematological malignancies

 Springer
releasing extracellular DNA traps contributing to ATE is being recognized as a cause of cerebrovascular and cardiovascular dysfunction seen in arterial thrombosis of hematological malignancies [25]. Platelets appear to play a vital role in ATE of hematological malignancies. Once activated, platelets change shape and degranulate to release growth factors and bioactive lipids into the blood stream. This cyclic process recruits more platelets and increases thrombogenesis. The inflammation/coagulation from malignancy including hematological malignancies activates neutrophils and induces them to form neutrophil extracellular traps (NETs). The NETs either directly or through the consequences of platelet activation causes thrombosis. This may lead to widespread myocardial microthrombosis, presenting as ischemic episodes with elevated levels of plasma troponin [26].

Abnormal Cellular Elements and Protein Molecules

The mechanisms for increased adhesion include overexpression of adhesion molecules such as selectins, which promote RBC adhesion to endothelium via laminin. In CML, tyrosine kinase inhibitors (TKI) including ponatinib inhibits numerous off targets, including vascular endothelial growth factor (VEGFR1-3), which may account for the systemic effect on the vasculature including arterial hypertension [27]. However, ponatinib acts as a platelet antagonist, and its effect on the vasculature is not secondary to platelet activation [28]. In myeloma there are high levels of inflammatory cytokines such as interleukin-6 and tumor necrosis factors [21, 22]. The JAK2 V617F mutation appears to increase proneness for thrombosis even without overt chronic myeloproliferative disorders [29, 30]. Platelet interaction with P-selectin demonstrates the integral role platelets play in the development of cancer-associated thrombosis [31].
Hematological Malignancies and ATE

Myeloproliferative Disorders

Essential Thrombocythemia, Myelofibrosis and Polycythemia Rubra Vera

In essential thrombocythemia (ET), ATE occurs more commonly than venous thrombosis [32]. The cumulative incidence of ATE in myeloproliferative disorders ranges from 54 to 80% [33]. The incidence of thrombosis at the time of diagnosis of patients with polycythemia rubra vera (PV) and ET is 9.7–38.6% with 64–96.7%, occurring in the arterial bed [34]. The overall cumulative rate of cardiac death was 7.2%, in myeloproliferative disorders [35]. It is postulated that JAK2 mutation leads to constitutive activation of the JAK2/STAT signaling pathway in myeloproliferative disorders, which in turn extends the inflammatory response or vice versa [36]. The risk of thrombosis in ET has been predicted by thrombosis history, older age, cardiovascular risk factors and JAK2V617F [37]. Extreme thrombocytosis (platelet count > 1000 × 10^9/L) was predicted as a risk factor for thrombosis, but this was proven inaccurate by the International Working Group studies, which found a reduced risk of arterial thrombosis in patients with very high platelet count in ET [38]. This can be explained by the occurrence of acquired von Willebrand syndrome in ET patients with extreme thrombocytosis, consistent with previous reports [39, 40]. In patients with ET a positive correlation was observed between JAK-2 V617F mutation, that facilitates erythropoietin receptor signaling, and thrombotic events, although the mechanism involved is not clear. In patients with PV, arterial hypertension and age 50–60 was associated with 2-fold increase of arterial thrombosis [41]. In patients with myeloproliferative disorders, ATE was reported to be responsible for the ischemic stroke, myocardial infarction and peripheral arterial occlusion [42]. Abnormalities of blood cells, activation of neutrophils and platelets, and a hypercoagulability state, can all act in conjunction to lead to thrombosis in myeloproliferative disorders [43]. In patients with PV and essential thrombocytopenia, cytoreduction protects against recurrent thrombosis [44].

Myelodysplastic Syndrome

In myelodysplastic syndrome (MDS), the burden of thrombotic events does not seem much higher than that of general population. This may be related to the low incidence of thrombosis due to high-frequency with thrombocytopenia and severe anemia. However, no clinical trials are available and retrospective studies are limited in size [45, 46]. The vascular risk seems to increase significantly when chemotherapeutic drugs such as thalidomide or lenalidomide are used with erythropoiesis-stimulating agents. But when erythropoiesis-stimulating agents are used alone in MDS, there does not appear to be an increased thrombotic risk [47]. Thrombosis related to MDS, has been associated with thrombotic thrombocytopenic purpura with occlusion of cardiovascular and abdominal vasculature [48]. Association of trisomy 8 in MDS has been reported as a risk factor for intestinal ulcers and thrombosis [49]. Acute Myocardial Infarction caused by thrombotic microangiopathy complicated by MDS needs antplatelet or anticoagulant therapy, despite severe pancytopenia and increased bleeding risk [50].

Chronic Myeloid Leukemia

Patients with chronic myeloid leukemia (CML), if properly managed, have an expected life span like the rest of the general population [33]. Proper management of CML often involves treatment with one of the tyrosine kinase inhibitors (TKIs). Pulmonary hypertension has been reported in patients treated with dasatinib. Dasatinib-induced exudative pleural effusion, a frequent adverse event occurring in 15% to 35% of patients [51, 52]. Ponatinib-associated vascular events (stroke, coronary artery stenosis, limb ischemia and occlusion, and venous thrombosis) occurred in 29% of patients [12]. Bosutinib-treated patients reportedly developed arterial hypertension [53]. In a systematic review, Haguët et al. found that 4.78% of patients developed arterial occlusive events with the new generation TKIs compared with 0.96% with imatinib. Ponatinib (OR 3.26; 95% CI 1.12–9.50), nilotinib (OR 3.69; 95% CI 2.29–5.95) and dasatinib (OR 3.32; 95% CI 1.37–8.01) are all associated with a higher risk of arterial occlusive events when compared to imatinib [54]. Nilotinib, dasatinib and ponatinib—are associated with arterial thrombosis, but no such adverse effects have been reported for imatinib. This includes coronary artery disease, peripheral vascular disease and cerebrovascular disease [55]. Thus, for example, nilotinib produces peripheral arterial disease in about 10% of patients [56]. Patients who develop peripheral arterial disease develop this complication early in their disease, suggesting that pre-existing risk factors exist for development of peripheral arterial disease, preferentially involving lower extremities and small vessels as seen in patients with diabetes mellitus [57]. In a multivariable logistic regression analysis comparing nilotinib, imatinib and no TKI, the imatinib-only cohort had decreased incidence of peripheral arterial disease versus the no-TKI cohort (OD 0.062; 95% CI 0.005–0.544) [58]. The exact pathophysiology of TKIs causing arterial occlusive phenomenon is not known, but
direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells has been postulated [59]. Nevertheless, according to the population-based studies, the life expectancy of CML is now associated the normal life expectancy for most patients, provided that patients take lifelong TKI/anti-thrombotic treatment regimen [60].

**Acute Leukemia**

Thrombotic complications in patients with acute leukemia occur frequently, significantly affecting morbidity and mortality [61]. Acute arterial occlusion in acute leukemia included cerebrovascular, cardiovascular and peripheral vascular occlusive disorders [62]. In 379 adult patients with newly diagnosed acute leukemia (ALL in 69 patients, acute promyelocytic leukemia (M3) in 31, and non-M3 AML in 279) 5 arterial thrombotic events were reported (AML type 5—in 2 patients, AML type 3—in two patients, AML type 1—in 1 patient and none in ALL) [63]. In acute promyelocytic leukemia (APL), thrombosis as a presenting symptom at diagnosis (which responds to effective therapy) occurs in 9.6% and in other types of acute myeloblastic leukemia in 3.2% of patients. The following factors are related to a higher incidence of thrombosis in APL: leukocytes \(> 10 \times 10^9/L\) (9% vs. 4%, \(p < 0.01\)), M3-variant subtype (11% vs. 4%, \(p = 0.02\)), fibrinogen \(< 170\) mg/dl (7% vs. 3%, \(p = 0.02\)) and hemoglobin \(> 10\) g/dl (8% vs. 4%, \(p = 0.03\)). No significant relation was observed with CD2 or other surface antigens, as well as FLT3 mutations [64]. Rashida et al., found 94 cases of ATE in patients with APL, out of which 80% occurred at the time of diagnosis. The coagulopathy in APL is multifactorial, with both disseminated intravascular coagulation and primary hyper-fibrinolysis mediated largely by the malignant leukocytes [65]. The specific antileukemia therapy including use of all trans-retinoic acid has been shown to reverse coagulopathy on APL [42, 66]. In patients with acute lymphoblastic leukemia, at the time of diagnosis, the incidence was reportedly low—just 1% [67]. The mechanism of arterial occlusion in patients with acute leukemia apart from APL is not known. Suggested mechanisms for ATE in acute leukemia include the combination of hyperleukocytosis and aggregation of platelets leading to arterial occlusion [68, 69].

**Lymphoproliferative Disorders**

**Hodgkin’s Lymphoma**

In Hodgkin’s lymphoma, accelerated coronary artery disease with increased mortality occurs with radiation to the mediastinum [70, 71]. Using the Surveillance Epidemiology and End Results (SEER) database from 2002 to 2011, the 6-month cumulative incidence of arterial thromboembolism in non-Hodgkin lymphoma was 5.4\% (95\% CI 5.1–5.8\%) compared with 2.2\% (95\% CI 2.0–2.4\%) in control patients (\(p < 0.001\)) [72]. Follow-up of a cohort of 7033 Hodgkin disease patients who were treated in UK—deaths from myocardial infarction was statistically significant (standardized mortality ratio [SMR] 2.5, 95\% confidence interval [CI] 2.1–2.9), with an absolute excess risk of 125.8 per 100,000 person-years [71]. Analysis of the treatment and follow-up records of 377 Hodgkin’s disease patients followed from January 1964 to September 1972, who received mantle irradiation, but no planned chemotherapy reveals an overall supradiaphragmatic relapse rate of 21\% with no vascular complications. Other complications of treatment included symptomatic pulmonary radiation reaction (20\%), pericarditis (13\%), Lhermitte’s sign (15\%), and thyroid dysfunction (13\%) [73].

**Non-Hodgkin’s Lymphoma**

In a retrospective review of acquired thrombophilia in lymphoproliferative disorders, Lechner et al. [74] analyzed 66 cases of immune-mediated thrombophilia in patients with lymphoma reported in the literature. They found 61 patients had lupus anticoagulant, out of which there were 7 patients had ATE. About 6.5\% had a catastrophic antiphospholipid antibody syndrome. In their analysis, incidence of arterial thromboembolism was half of venous thromboembolic episodes. T cell lymphoma presenting as hyper-eosinophilic syndrome was associated with arterial thrombosis in 40\%, with mixed arterial and venous thrombosis in 27\% [75]. Patients treated with doxorubicin for diffuse large B-cell lymphoma develop not only cardiomyopathy, but also accelerated coronary artery disease with high cardiovascular mortality as a late complication with this agent [76]. Thrombotic occlusions of the popliteal and tibial arteries are reported in patients with Castleman’s disease [77]. Intravascular large B-cell lymphoma is associated with arterial occlusion [75]. Treatment induced microvascular induced neurotoxicity of chemo-radiation therapy of CNS lymphoma include: vincristine neuropathy, ifosfamide or cytarabine encephalopathy, radiation myelopathy, or radiation related cognitive impairment [78]. The risk of radiation induced vasculopathy or myelopathy following conventionally fractionated radiotherapy to the spinal cord for spinal cord involvement by Non-hodgkin’s lymphoma is extremely small [79].

**Bone Marrow Transplantation**

Following hematopoietic stem cell transplantation, thrombotic microangiopathy was seen in 20\% of kidneys at
Patients developed ATE during warfarin treatment, myeloma developed cerebral arterial ischemia [90]. et al. reported 2 out of 23 patients on thalidomide for year of therapy for patients with myeloma [89]. Bowcock [87]. The incidence of ATE was nearly 2-fold during first VIII levels contributed to the risk of arterial thrombosis. In this study, hypertension, smoking and elevated factor [88]. In a prospective cohort study, Libourel et al. reported brovascular thrombosis in MM is about 7.45% in 5 years [91]. Other novel agents include small interfering RNAs is being explored as a treatment option in reducing the expression of the amyloid precursor protein. The in vitro studies show inhibition of synthesis of light chains in transfected cells, and in vivo there is reduction in the production of circulating free light chains [100]. In light chain amyloidosis, the most common type of amyloidosis treatment with bortezomib, lenalidomide, dexamethasone, renal transplantation followed by autologous stem cell transplantation, the 1- and 5-year overall survival has increased to 84% and 76%, respectively [98].

Systemic Amyloidosis

Arterial thrombosis in AL-amyloidosis, especially coronary thrombosis occurs in nearly 50% of patients with 26% mortality [94]. Intracardiac thrombosis and thromboembolic events occurred in 26–33% of patients with primary amyloidosis (AL type) with preserved left ventricular ejection fraction [94]. AL-amyloidosis can occur de novo, or from excess light chain deposition from hematological diseases including multiple myeloma, Waldenström’s macroglobulinemia and non-Hodgkin’s lymphoma [95].

Mechanisms of ATE in cardiac amyloidosis include hypercoagulability, endothelial dysfunction, endomyocardial damage, direct myocardotoxic effects and left ventricular diastolic dysfunction [96]. Antithrombotic treatment in AL amyloidosis is complicated by bleeding tendencies secondary to acquired factor X deficiency [97]. The treatment of ATE is directed against underlying disease process. This includes alkylator-based chemotherapy, immunomodulatory agents, proteasome inhibitors and stem cell transplantation after high-dose chemotherapy [98].

Plasma Cell Dyscrasias

Myeloma

Arterial thrombosis (coronary artery disease, cerebrovascular disease, myocardial infarction) occur during or soon after induction chemotherapy/immunotherapy for multiple myeloma (MM) [87]. The cumulative incidence of cerebrovascular thrombosis in MM is about 7.45% in 5 years [88]. In a prospective cohort study, Libourel et al. reported 5–12.5% of ATE in MM patients treated with Thalidomide. In this study, hypertension, smoking and elevated factor VIII levels contributed to the risk of arterial thrombosis [87]. The incidence of ATE was nearly 2-fold during first year of therapy for patients with myeloma [89]. Bowcock et al. reported 2 out of 23 patients on thalidomide for myeloma developed cerebral arterial ischemia [90]. Patients developed ATE during warfarin treatment, suggesting that warfarin is not sufficient as prophylactic treatment in MM patients who are at high risk for arterial thrombosis [87].

Propylactic aspirin is used in myeloma to prevent both arterial and venous thromboembolic episodes [91]. The incidences of myocardial infarction and cerebrovascular events were 1.98% and 3.4%, respectively, in patients treated with lenalidomide and dexamethasone compared with 0.57% and 1.7%, in patients treated with dexamethasone alone [3]. The incidence of ATE with the newer agent, pomalidomide is not known. Bortezomib has a protective effect on thromboembolic phenomena in patients with myeloma, as platelet aggregation induced by the agonists were decreased after exposure to bortezomib. Patients may not routinely need thromboprophylaxis for combination therapy regimens with bortezomib in multiple myeloma [92]. However, with novel agents, the overall survival for patients diagnosed with myeloma between 2006 and 2010 has increased to 6.1 years [93].
Miscellaneous

Radiation Therapy

Ionizing radiation leads to release of superoxide, hydrogen peroxide and hydroxyl radicals which cause endothelial damage and activation of coagulation cascade [100]. Ionizing radiation leads to perivascular edema at 4–8 weeks and initiation of fibrosis after 20 weeks [101]. There was a 3.6-fold increased incidence of myocardial infarction at 19-year follow-up in patients with Hodgkin disease [102]. The release of cytokines including transforming growth factor beta, induces proliferation of fibroblasts and accelerated atherosclerosis [103]. The ‘oxygen effect’, is the radiation effect of the tissues secondary to superoxide radicles (less sensitive at lower level of oxygen). The dose, the technique (Intensity modulated radiation therapy versus three dimensional configuration), extent of the vasculature exposed decides the extent of atherosclerosis and arterial thrombosis [103]. Radiation induced arterial thrombosis is secondary to accelerated atherosclerosis, leading to vascular events like stroke, coronary artery disease, and peripheral artery disease. This is dependent on the radiation dose and technique and extent of vasculature exposed [104]. There is a greater risk of radiotherapy-induced vascular diseases in younger patients when irradiating the mediastinum, in the treatment of Hodgkin’s disease, when compared to the elderly [105]. The incidence of coronary artery disease risk is proportional to the radiation dose to the heart and can be seen within 5 years of radiotherapy but typically presents in the second to third decade post-therapy [106]. The manifestation of atherosclerotic process in these vessels include: stenosis, thrombosis, and aneurysmal dilatation [107]. Occlusive arterial disease within the irradiated field with relative sparing of non-irradiated arteries is highly suggestive of radiation-induced occlusive arterial disease [104]. Variety of endovascular and surgical procedures are used to treat radiation-induced occlusive disease [108]. Hodgkin’s disease survivors are at 2- to 12-fold increased risk of CV mortality when compared to controls, largely attributable to myocardial infarction [71, 109]. Total body radiation used as conditioning regimen in bone marrow transplantation for myelodysplastic syndrome and acute leukemia (in particular acute leukemia in childhood), was not associated with ATE, especially coronary artery disease unless there was mediastinal irradiation [110].

Antiphospholipid Syndrome, Disseminated Intravascular Coagulation and Heparin-Induced Thrombocytopenia

In disseminated intravascular coagulation (DIC), ATE occurs in about 3% of patients with hematological malignancies. Without effective control of the underlying cause, treatment of DIC is not usually successful [111]. A higher rate of ATE was observed in patients with heparin-induced thrombocytopenia (HIT) and malignancy, when compared to patients with no underlying malignancy (odds ratio 13.6, 95% confidence interval 2.9–63.8) [112]. The antiphospholipid syndrome has been associated with hematological malignancies [113]. Lupus anticoagulant was present in 41% of patients with aggressive non-Hodgkin’s lymphoma which correlated with shortened survival [114]. Cerebral manifestations were most common and consisted mainly of cerebral infarcts and encephalopathy [114]. Platelet-leukocyte-endothelial aggregates generate HIT-specific thrombosis. Arterial thromboembolic episodes including stroke, acute myocardial infarction, mesenteric, renal, aortic and limb arterial occlusion can occur in patients with HIT [115].

Therapy-Related Arterial Thrombosis

Potentially fatal complication affecting mostly the kidneys and the brain microvascular changes occur with cisplatin, bleomycin and gemcitabine. Cisplatin induced endothelial vascular damage leads to coronary artery disease, but if this is dose dependent is not known [116, 117]. Vinca alkaloids and mitomycin C are associated with disseminated intravascular coagulation [118, 119]. Rituximab generally is a well-tolerated medication, but rituximab-induced coagulopathy with thrombocytopenia and disseminated intravascular coagulation is reported following rituximab administration [120]. Therapy with CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells can be complicated by neurologic adverse events in patients with refractory B-cell malignancies. Patients with severe neurotoxicity demonstrated evidence of endothelial activation, including disseminated intravascular coagulation, capillary leak, and increased blood–brain barrier permeability [121].

Growth Factors and Arterial Events

The hematopoietic growth factors such as erythropoietin, granulocyte colony-stimulating factor and macrophage-granulocyte colony-stimulating factor have been implicated in ATE [117]. The erythropoietin receptor is widely distributed in endothelial cells, smooth muscle cells and cardiomyocytes. An increase in cardiovascular events, vascular access thrombosis, stroke and myocardial infarction, has been associated with erythropoietin [122]. Granulocyte colony-stimulating factor can cause acute arterial occlusion due to platelet aggregation [123]. Macrophage-granulocyte colony-stimulating factor (GM-CSF) causing thrombosis of common, internal and external iliac arteries has been reported in patients receiving chemotherapy.
Growth factors do not directly modulate endothelial cell function, but this may be related to activation of coagulation factors and hemostasis [125]. Macrophage-granulocyte colony-stimulating factor leads to the release of secondary cytokines, including tumor necrosis factor (TNF) and interleukin-1 (IL-1), which are associated with alterations in coagulation [126]. Hematopoietic growth factors along with chemotherapy enhances endothelial cell reactivity to platelets causing ATE [127].

**Prediction and Risk Assessment Model for Arterial Thrombosis in Hematological Malignancies**

There is no risk assessment model or predictive score available for predicting arterial thromboembolism in cancer patients [128]. The existing risk assessment models including Khorana, Vienna, Protecht, and Concho scores in venous thrombosis, are not applicable in arterial thrombosis [128].

**Algorithm for management of arterial thrombosis in hematological malignancies: Fig. 3**

There are no standard guidelines for management of arterial thrombosis in hematological malignancies. Treatment of ATE is individualized, based on clinical condition of the patient, rapidity of the onset and the associated comorbidities. The underlying incriminating agent (TKIs, immunomodulatory agents, growth factors including erythropoietin), must be withheld and appropriate measures taken to improve the blood supply to the vascular territory. Treatment usually involves a multidisciplinary approach involving internists, intensivists, interventional radiologists and the surgical teams. The treatment algorithm, is based on the clinical scenario, underlying hematological disorder, pre-existing comorbidities, identifiable hypercoagulable state and previous treatment received by the patient. In the absence of clear data from randomized studies and guidelines for recommendations, our aim is to provide a rational approach to the management of ATE in hematological malignancies based on clinical experience, acknowledging that there is no evidence-based algorithm available for this entity.

**Prophylaxis**

Primary prophylaxis for arterial thrombosis in outpatient setting of ambulatory patients is precluded by lack of data of the benefit, except in patients with chronic myeloid leukemia, myelofibrosis and myeloma. Primary prevention of arterial thrombosis with antiplatelet therapy is warranted for patients with myeloproliferative disorders, for patients receiving TKIs in chronic myeloid leukemia, immunomodulatory therapy for myeloma, age above 60, or with history of previous history of ATE. The role of anticoagulant therapy preventing ATE in hematological malignancies is not yet proven. Prophylaxis may be considered for patients receiving chemotherapy with previous history of DVT/PE, as studies have shown that previous history of venous thrombosis especially in unprovoked

---

**Fig. 3** Proposed algorithm for management of ATE in hematological malignancies

- **Diagnosis with Physical examination, arterial Doppler/and or arteriography**
- **Risk assessment - comorbid factors including obesity, hypertension, diabetes and dyslipidemia, vitals, CBC, Lupus anticoagulant, EKG & TEE**
- **Hold Chemotherapy, TKIs or immunomodulatory therapy/ / CT chest/ Abd. If needed**
- **Acute**
  - Tt. Shock, thrombolysis, endarterectomy/bypass Sx
  - Continue antithrombotic and antiplatelet therapy
- **Chronic**
  - Treatment of comorbidities, antithrombotic and antiplatelet therapy

TEE – trans-esophageal echocardiogram
setting, leads to arterial thrombosis [129]. There appears to be emerging evidence for primary thromboprophylaxis, based on risk assessment with biomarker screening including P-selectin, CRP, factor VIII, prothrombin F 1 + 2, and TF-bearing microparticle levels in patients with cancer, but these are not yet validated [130].

**Management**

There is no randomized controlled trial available to guide the clinician for the management of ATE in hematological malignancies. Treatment for ATE may need to be individualized (smoking cessation, controlling weight and treatment of co-morbidities). Occasionally, patients may have vasculitis or patent foramen ovale causing ATE, independent of hematological malignancies. After initial assessment, the medical management for acute arterial or venous thromboembolism appear to be similar—Fig. 3.

The initial treatment is intravenous heparin or low-molecular-weight heparin [131]. Concurrent antiplatelet agents and/or statins along with anticoagulant therapy is suggested for ATE. Life-threatening arterial thrombotic events may need endoluminal revascularization and surgical procedures including angioplasty, thrombo-embolectomy and arterial bypass have mixed results [6].

In non-life-threatening ATE, the treatment paradigm includes thrombolytic therapy with streptokinase or urokinase or combination of both, LMWH and newer agents including recombinant tissue factor pathway inhibitor and anti-tissue factor monoclonal antibodies [132, 133]. Promising agents under evaluation for micro-thrombosis secondary to thrombotic thrombocytopenic purpura include, caplacizumab (an inhibitor of the glycoprotein-1b/IX-Von-Willebrand factor axis), N-acetyl cysteine, recombinant ADAMTS13, and anti-plasminocytoid compounds [134]. When long-term anticoagulation is advised, careful consideration should be given to the risk associated with therapy [131]. A conservative nonsurgical therapeutic approach was suggested for patients with peripheral arterial occlusion, because of poor outcome with increased post-operative mortality (as high as 80–100%) [8].

**Prognosis**

Arterial thrombosis is associated with higher mortality when compared with age adjusted controls with systemic vascular disease in malignant hematological disorders [132]. Even with specific surgical intervention of arterial thrombosis in active malignancy, the outcome is very bleak [8]. About 80% of patients die within 1 year, compared to 80% survival during the same time period without cancer from atherosclerotic vascular disease [8, 135]. In malignancy, including hematological malignancies, the survival rate from the time of presentation of arterial thrombosis was 50% at 3 months and 17% at 1 year [8]. Therefore, aggressive management for pre-existing risk factors including tobacco use, hypertension, dyslipidemia, increasing age, obesity, metabolic syndrome, renal failure, hyper-homocystinemia and diabetes mellitus is needed for patients with cancer, but value of this in preventing arterial thrombosis is questionable.

**Future Perspectives**

The data on ATE in hematological malignancies is just emerging. From a preclinical stand point, the more we learn about the biology of ATE, the better we understand the mechanisms altered in hematological malignancies. This will also help us understand the role of targeted therapies incriminated in ATE. There are more novel therapies in pipeline, aimed to improve the overall survival of patients with hematological malignancies. We need randomized controlled trials for prophylaxis and treatment of ATE. There is a need for epidemiological studies to ascertain the incidence of ATE in malignant hematological disorders. This may help us with the appropriate prophylaxis and treatment of ATE in individual clinical entities.

**Conclusion**

Arterial thromboembolism is a serious complication with high mortality in patients with hematological malignancies. The landscape appears to be bright for hematological malignancies with major breakthroughs in the treatment, including the next generation tyrosine kinase inhibitors, immunomodulatory agents, proteasome inhibitors and monoclonal antibodies. We need innovative approaches to decrease the incidence of ATE including: (a). appropriate prophylaxis (aspirin with ponatinib/immunomodulatory therapy) (b). identifying chemotherapeutic agents with increased incidence of ATE (cisplatin) (c). Concurrent use of agents (proteasome inhibitors and immunomodulatory agents) (d). avoiding precipitating agents (use of tobacco, habituating agents including cocaine) and (e). appropriate management of comorbidities including diabetes mellitus, dyslipidemia, atrial fibrillation and obesity. Some of these strategies have already proven to be successful. Early recognition and appropriate intervention may improve recovery and decrease mortality of ATE in hematological malignancies.

**Acknowledgements** We would like to thank Beth Schachter, PhD for final revision of our manuscript.
Compliance with Ethical Standards

Conflict of interest All authors declare that they have no conflict of interest.

Human and Animals Rights This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Blann AD, Dunmore S (2011) Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011:394740. https://doi.org/10.4061/2011/394740

2. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

3. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G et al (2016) Cardiovascular complications of novel multiple myeloma treatments. Circulation 133(9):908–912. https://doi.org/10.1161/circulationaha.115.018351

4. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NW et al (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29(25):3466–3473. https://doi.org/10.1200/jco.2011.35.5669

5. Lowe GD (2007) Is venous thrombosis a risk factor for arterial thrombosis? Lancet Lond (Eng) 370(9601):1742–1744. https://doi.org/10.1016/S0140-6736(07)61731-0

6. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P, Molinari N et al (2015) Venous thrombosis and risk of cancer in patients with arterial cardiovascular disease: a 20-year cohort study. Lancet Lond (Eng) 370(9601):1773–1779. https://doi.org/10.1016/S0140-6736(07)61745-0

7. Schmidt SA, Sarkas DK, Pedersen L, Prandoni P, Sorensen HT (2015) Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet Lond (Eng) 370(9601):1773–1779. https://doi.org/10.1016/S0140-6736(07)61745-0

8. Nascito J, Yeshurun D, Abrahamson J (1992) Arterial occlusive disease in occult cancer. Am Heart J 124(3):738–745

9. Schmaier AH, Merkulova AA, Mitchell S, Stavrou EX (2016) Ponatinib and cardiovascular complications. Blood 128:3055

10. Connolly GC, Phipps RP, Francis CW (2014) Platelets and cancer-associated thrombosis. Semin Oncol 41(3):302–310. https://doi.org/10.1053/j.seminoncol.2014.04.009

11. Eliasson A, Bergqvist D, Bjorck M, Acosta S, Sternby NH, Ogren M (2006) Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost JTH 4(9):1897–1902. https://doi.org/10.1111/j.1538-7836.2006.02152.x

12. Hong C, Zhu F, Du D, Pilgram TK, Picard GA, Bae KT (2005) Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 181(1):169–174. https://doi.org/10.1016/j.atherosclerosis.2005.03.047

13. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

14. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

15. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

16. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

17. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

18. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

19. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547

20. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133(13):1272–1289. https://doi.org/10.1161/circulationaha.115.018547
signaling, platelet activation and aggregate formation under shear. Thromb Res 135(1):155–160. https://doi.org/10.1016/j.thromres.2014.11.009

29. Cell G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L et al (2010) Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 104(1):151

30. De Grandis M, Cambot M, Wautier M-P, Cassinat B, Chomienne C, Colin Y et al (2012) JAK2V617F activates La/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood 12:68–665

31. Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG (2016) Cancer and Thrombosis: the Platelet Perspective. Front Cell Dev Biol 4:147. https://doi.org/10.3389/fcell.2016.00147

32. Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33(4):313–320. https://doi.org/10.1055/s-2007-976165

33. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T (1998) No treatment for low-risk thrombocytopenia: results from a prospective study. Br J Haematol 103(3):772–777

34. Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22(11):2020–2028. https://doi.org/10.1038/leu.2008.253

35. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782

36. Muendlein K, Kinz E, Gasser K, Leiferer A, Rein P, Saely CH et al (2015) Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease. Am J Hematol 90(1):E17–E21. https://doi.org/10.1002/ajh.23874

37. Tefferi A, Barbui T (2013) Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia 27(8):1617–1620. https://doi.org/10.1038/leu.2013.99

38. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857–5859. https://doi.org/10.1182/blood-2011-03-339002

39. Budde U, Dent J, Berkowitz S, Ruggieri Z, Zimmerman T (1986) Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 68(6):1213–1217

40. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F et al (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112(8):3135–3137

41. Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H et al (2017) The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol 92(1):E5–E6. https://doi.org/10.1002/ajh.24583

42. Falanga A, Barbui T, Rickles FR (2008) Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 34(2):204–210. https://doi.org/10.1055/s-2008-1079262

43. Kogan I, Chap D, Hoffman R, Axelmen E, Brenner B, Nadir Y (2016) JAK-2 V617F mutation increases heparanase procoagulant activity. Thromb Haemost 116(1):73–80

44. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372–380

45. Landolfi R, Di Gennaro L (2012) Thrombosis in myeloproliferative and myelodysplastic syndromes. Hematology 17(Suppl 1):S174–S176. https://doi.org/10.1179/102453312x13336169156898

46. Aquayo A, Armillas-Canseco FM, Martinez-Banos D (2011) Antiangiogenesis in myelodysplastic syndrome. Curr Cancer Drug Targets 11(9):1044–1052

47. Smith SW, Sato M, Gere SD, Baer MR, Ke X, McNally D et al (2012) Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 97(1):15–20. https://doi.org/10.3324/haematol.2011.051755

48. Perez L, Ramappa P, Guzman JA (2008) Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication. Int J Cardiol 128(2):257–260. https://doi.org/10.1016/j.ijcard.2007.04.181

49. Chen HC, Chiu YM (2012) Large-vessel thrombosis in intestinal Behcet’s disease complicated with myelodysplastic syndrome and trisomy 8. World J Gastroenterol 18(10):1137–1140. https://doi.org/10.3748/wjg.v18.i10.1137

50. Oshima T, Kitomori M, Shinozaka H, Ishiwata J, Fukino K, Amaki T et al (2016) Acute myocardial infarction caused by thrombotic microangiopathy complicated with myelodysplastic syndrome. Int Heart J 57(5):634–636. https://doi.org/10.1536/ihj.16-100

51. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17):2128–2137. https://doi.org/10.1161/circulationaha.111.079921

52. Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908–3914. https://doi.org/10.1200/jco.2007.12.0329

53. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P (2015) Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125(6):901–906. https://doi.org/10.1182/blood-2014-09-594432

54. Huguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM (2017) Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 16(1):5–12

55. Aichberger KJ, Herndrofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C et al (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86(7):533–539. https://doi.org/10.1002/ajh.22037

56. le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndrofer S et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103(17):1347–1348. https://doi.org/10.1093/jnci/djr292

57. Aboyans V, Lacroix P, Criqui MH (2007) Large and small vessels atherosclerosis: similarities and differences. Prog Cardiovasc Dis 50(2):112–125. https://doi.org/10.1016/j.pcad.2007.04.001

58. Giles F, Mauro M, Hong F, Ortmann C, McNelll C, Woodman R et al (2013) Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27(6):1310

59. Racil Z, Razga F, Drapalova I, Buvesova L, Zackova D, Palackova M et al (2013) Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 98(10):e124–e126. https://doi.org/10.3324/haematol.2013.086355

60. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with
chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851–2857. doi:10.1200/jco.2015.66.2866

61. Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program 2012:571–581. https://doi.org/10.1182/asheducation-2012.1.571

62. Rashidi A, Silverberg ML, Conkling PR, Fisher SI (2013) Thrombosis in acute promyelocytic leukemia. Thromb Res 131(4):281–289. https://doi.org/10.1016/j.thromres.2012.11.024

63. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L et al (2005) The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 3(9):1985–1992

64. Montesinos P, de la Serna I, Vellenga E, Rayon C, Bergua J, Parody R et al (2006) Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 protocols. Am Soc Hematol Protocols

65. Mantha S, Tallman MS, Soff GA (2016) What’s new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? Curr Opin Hematol 23(2):121–126. https://doi.org/10.1097/moh.0000000000000221

66. Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114(25):5126–5135. https://doi.org/10.1182/blood-2009-07-216457

67. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L et al (2005) The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost JTH 3(9):1985–1992. https://doi.org/10.1111/j.1538-7836.2005.01467.x

68. Kafetzakis A, Foundoulakis I, Ioannou CV, Stavroulaki E, Koutsopoulos A, Katsamouris AN (2007) Acute lower limb ischemia as the initial symptom of acute myeloid leukemia. Vasc Med 12(3):199–202. https://doi.org/10.1177/1358863x07080630

69. Fass R, Haddad M, Zaiwz R, Sandbank Y, Yaniv I, Cohen IJ et al (1992) Recurrent peripheral arterial occlusion by leukemic cells sedimentation in acute promyelocytic leukemia. J Pediatr Surg 27(5):665–667

70. Andersso R, Naslund U, Tavelin B, Enblad G, Gustavsson A, Malmer B (2009) Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors–retrospective cohort analyses and a concept for prospective intervention. Int J Cancer 124(8):1914–1917. https://doi.org/10.1002/ijc.24147

71. Swerdlov AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A et al (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206–214. https://doi.org/10.1093/jnci/djk029

72. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV et al (2005) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70(8):926–938. https://doi.org/10.1016/j.jacc.2017.06.047

73. Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s disease. An analysis of technique, tumor eradication, and complications. Cancer 37(6):2813–2825

74. Lechner K, Simonitsch J, Haselbäck J, Jäger U, Pabinger I (2011) Acquired immune-mediated thrombophilia in lymphoproliferative disorders. Leuk Lymphoma 52(10):1836–1843

75. Maino A, Rossio R, Cugno M, Marzano AV, Tedeschi A (2012) Hypereosinophilic syndrome. Chung–Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr Vasc Pharmacol 10(5):670–675

76. Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J et al (2005) Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma 6(2):122–130. https://doi.org/10.3816/CLM.2005.n.038

77. Schumacher A, Jacob V, Stussi G, Amann-Vesti B, Corti N, Husmann M (2012) Castleman’s disease and arterial thrombosis: result of excessively elevated interleukin-6 plasma level? VASA Z Gefasskrankh 41(2):145–148. https://doi.org/10.1024/0301-1526/a000178

78. DeAngelis LM (1999) Primary central nervous system lymphoma. BMJ Publishing Group Ltd, London

79. Wong CS, Van Dyk J, Milosevic M, Laperriere NJ (1994) Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 30(3):575–581

80. Chamsirikutchai S, Myersson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR (2009) Renal thrombotic microangiopathy after hematopoietic cell transplantation: role of GVHD in pathogenesis. Clin J Am Soc Nephrol CIASN 4(2):345–353. https://doi.org/10.2215/cjn.02070508

81. Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JH (2014) Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer 120(9):1426–1432. https://doi.org/10.1002/cncr.28547

82. Garcia-Martín P, Alarcon-Payer C, Lopez-Fernandez E, Moratalla L, Romero A, Sainz J et al (2015) Transplantation-associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease. Ann Pharmacother 49(9):986–994. https://doi.org/10.1177/1060028015593369

83. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al (2004) Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transpl 10(5):328–336. https://doi.org/10.1016/j.bbmt.2003.12.305

84. George JN, Selby GB (2004) Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transpl 33(11):1073–1074. https://doi.org/10.1038/sj.bmt.1704513

85. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al (2005) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 11(8):571–575

86. Rosenthal J (2016) Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med 7:181–186. doi:10.1524/jbmt.101.15235

87. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW (2010) High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 116(1):22–26. https://doi.org/10.1182/blood-2009-12-257519

88. Lee GY, Lee YT, Yeh CM, Hsu P, Lin TW, Gau JP et al (2016) Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study. Hematol Oncol. https://doi.org/10.1002/hon.2340

89. Kristinson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Bliemar C et al (2012) Monoclonal gammapathy of undetermined significance and risk of infections: a population-based study. Haematologica 97(6):854–858. https://doi.org/10.3324/haematol.2011.054015

90. Bowcock SJ, Rassam SM, Ward SM, Turner JT, Laffan M (2002) Thrombembolism in patients on thalidomide for myeloma. Hematology 7(1):51–53
91. Yokoyama K (2015) Thrombosis in Lymphoma Patients and in Myeloma Patients. Keio J Med 64(3):37–43. https://doi.org/10.2302/kjm.2014-0017-RE
92. Shen Y, Zhou X, Wang Z, Yang G, Jiang Y, Sun C et al (2011) Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res 35(2):147–151. https://doi.org/10.1016/j.leukres.2010.08.007
93. Kumar SK, Dispensieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122
94. Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420–2426. https://doi.org/10.1161/circulationaha.107.697763
95. Halligan CS, Lacy MQ, Vincent Rajkumar S, Dispenzieri A, Witzig TE, Lust JA et al (2006) Natural history of thrombocytopenia in AL amyloidosis. Amyloid 13(1):31–36. https://doi.org/10.3109/13506120500537285
96. Fujita T, Ichikawa S, Okutsu Y, Fukushima N, Yoshinaga T, Yazaki M et al (2016) Primary AL amyloidosis presenting with systemic lymphadenopathy with calcification. Int J Hematol 104(6):641–643. https://doi.org/10.1007/s12185-016-2090-3
97. Choufani EB, Sanchovarala V, Ernst T, Quillen K, Skinner M, Wright DG et al (2001) Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 97(6):1885–1887
98. Mahmood S, Palladini G, Sanchvarala V, Wechalekar A (2014) Update on treatment of light chain amyloidosis. Hematologica 99(2):209–221. https://doi.org/10.3324/haematol.2013.087619
99. O’Nuallain B, Hrnčic R, Wall JS, Weiss DT, Solomon A (2006) Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol (Baltimore, Md: 1950) 176(11):7071–7078
100. Hovey BM, Ward JE, Soo Hoo P, O’Hara CJ, Connors LH, Seldin DC (2011) Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther 18(12):1150–1156. https://doi.org/10.1038/gt.2011.69
101. Rodemann HP, Bamberg M (1995) Cellular basis of radiation-induced fibrosis. Radiother Oncol 35(2):83–90
102. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MH, de Boer JP et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5):1878–1886. https://doi.org/10.1182/blood-2006-07-034405
103. Burger A, Loffler H, Bamberg M, Rodemann HP (1998) Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol 73(4):401–408
104. Jurado JA, Bashir R, Burkett MW (2008) Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 72(4):563–568. https://doi.org/10.1002/ccd.21681
105. Richardson RB (2008) Age-dependent changes in oxygen tension, radiation dose and sensitivity within normal and diseased coronary arteries-Part C: oxygen effect and its implications on high- and low-LET dose. Int J Radiat Biol 84(10):858–865. https://doi.org/10.1080/09553000802389866
106. Schellong G, Riepenhausen M, Bruch C, Kothhoff S, Vogt J, Bolling T et al (2010) Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55(6):1145–1152. https://doi.org/10.1002/pbc.22664
107. Won KB, Kim BK, Ko YG, Hong MK, Choi D, Jang Y (2012) Arterial occlusive disease complicating radiation therapy of cervical cancer. Yonsei Med J 53(6):1220–1223. https://doi.org/10.3349/yjm.2012.53.6.1220
108. Bentzen SM, Overgaard J (1994) Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol 4(2):68–80. https://doi.org/10.1053/srao.0000068
109. van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM et al (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175(6):1007–1017. https://doi.org/10.1001/jama.2015.1180
110. Leiper AD (1995) Late effects of total body irradiation. Arch Dis Child 72(5):382
111. Sack GH Jr, Levin J, Bell WR (1977) Troussseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 56(1):1–37
112. Opatrny L, Warner MN (2004) Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 76(3):240–244. https://doi.org/10.1002/ajh.20098
113. Lazzaroni MG, Taglietti M, Tincani A (2014) Malignancies: a possible “first hit” in the development of catastrophic antiphospholipid syndrome? Israel Med Assoc J 16(9):583–584
114. Miesbach W, Asherson RA, Cervera R, Shoenefeld Y, Gomez Puerta J, Bucciarelli S et al (2006) The catastrophic antiphospholipid (Asherson’s) syndrome and malignancies. Autoimmun Rev 6(2):94–97. https://doi.org/10.1016/j.autrev.2006.06.012
115. Emadi A, Streiff M (2011) Management of acquired thrombophilic disorders in 2011: focus on heparin-induced thrombocytopenia, antiphospholipid syndrome, myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria. Arch Iran Med 14(6):401–411. https://doi.org/011146/AIM.009
116. Kheder El-Fekih R, Deltombe C, Izzedine H (2017) Thrombotic microangiopathy and cancer. Nephrol Ther 13(6):439–447. https://doi.org/10.1016/j.nephro.2017.01.023
117. Nadir Y, Hoffman R, Brenner B (2004) Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 8(1):E4
118. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM et al (2006) Intracardiac thrombosis and embolism in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 76(3):240–244. https://doi.org/10.1002/ajh.20098
119. Li H, Sasano Y, Hori K, Manabu K, Zhang Q, Saito S et al (1998) Hypercoagulable state and disseminated intravascular coagulation following an effective chemotherapy in tumor-bearing rats. Chin Med J 111(10):951–955
120. Rafei H, Nassereddine S, Garcia IF (2017) Disseminated intravascular coagulation-like reaction following rituximab infusion. BMJ Case Rep. https://doi.org/10.1136/bcr-2016-21443
121. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF et al (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 7(12):1404–1419. https://doi.org/10.1158/2159-8290.cd-17-0698
122. Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59(3):538–548
123. Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Seta K (1996) Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. Br J Haematol 94(2):413–416

© Springer
124. Tolcher AW, Giusti RM, O’Shaughnessy JA, Cowan KH (1995) Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. Cancer Invest 13(2):188–192

125. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O et al (1991) In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 87(3):986–995. https://doi.org/10.1172/jci115107

126. Sisson SD, Dinarello CA (1988) Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood 72(4):1368–1374

127. Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR (1990) Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metab 8(6):511–518

128. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I et al (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102(9):1494–1501. https://doi.org/10.3324/haematol.2017.169060

129. Toft H, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P (2007) Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370(9601):1773–1779

130. Connolly GC, Khorana AA (2010) Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 125(Suppl 2):S1–S7. https://doi.org/10.1016/s0049-3848(10)00227-6

131. Baker WF Jr, Bick RL (1999) Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25(4):387–406. https://doi.org/10.1055/s-2007-994942

132. Thalin C, Demers M, Blomgren B, Wong SL, von Arbin M, von Heijne A et al (2016) NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb Res 139:56–64. https://doi.org/10.1016/j.thromres.2016.01.009

133. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL et al (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2):238–247. https://doi.org/10.1001/jama.290.2.238

134. Coppo P (2017) Management of thrombotic thrombocytopenic purpura. Transfus Clin Biol 1:1. https://doi.org/10.1016/j.trabc.2017.05.015

135. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl 1):S1–S75. https://doi.org/10.1016/j.ejvs.2006.09.024

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.